Next Article in Journal
Oncolytic Replication of E1b-Deleted Adenoviruses
Next Article in Special Issue
Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection
Previous Article in Journal
Human T-Lymphotropic Virus Type I (HTLV-1) Infection among Iranian Blood Donors: First Case-Control Study on the Risk Factors
Previous Article in Special Issue
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
Open AccessReview

Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications

1
Liver Unit, Internal Medicine, Laboratory of Malalties Hepàtiques, Vall d’Hebron Institut de Recerca-Hospital Universitari Vall d’Hebron (VHIR-HUVH), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
2
Centro de Biologia Molecular “Severo Ochoa” (CSIC-UAM), Cantoblanco, 28049 Madrid, Spain
3
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 08035 Barcelona, Spain
4
Universitat Autònoma de Barcelona, Bellaterra 08193, Spain
5
Roche Diagnostics SL, 08174 Sant Cugat del Vallès, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Thomas Baumert
Viruses 2015, 7(11), 5746-5766; https://doi.org/10.3390/v7112902
Received: 22 September 2015 / Revised: 23 October 2015 / Accepted: 26 October 2015 / Published: 6 November 2015
(This article belongs to the Special Issue HCV Drug Resistance)
Selection of inhibitor-resistant viral mutants is universal for viruses that display quasi-species dynamics, and hepatitis C virus (HCV) is no exception. Here we review recent results on drug resistance in HCV, with emphasis on resistance to the newly-developed, directly-acting antiviral agents, as they are increasingly employed in the clinic. We put the experimental observations in the context of quasi-species dynamics, in particular what the genetic and phenotypic barriers to resistance mean in terms of exploration of sequence space while HCV replicates in the liver of infected patients or in cell culture. Strategies to diminish the probability of viral breakthrough during treatment are briefly outlined. View Full-Text
Keywords: viral quasi-species; hepatitis C virus; viral resistance; antiviral treatment viral quasi-species; hepatitis C virus; viral resistance; antiviral treatment
Show Figures

Figure 1

MDPI and ACS Style

Perales, C.; Quer, J.; Gregori, J.; Esteban, J.I.; Domingo, E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses 2015, 7, 5746-5766. https://doi.org/10.3390/v7112902

AMA Style

Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015; 7(11):5746-5766. https://doi.org/10.3390/v7112902

Chicago/Turabian Style

Perales, Celia; Quer, Josep; Gregori, Josep; Esteban, Juan I.; Domingo, Esteban. 2015. "Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications" Viruses 7, no. 11: 5746-5766. https://doi.org/10.3390/v7112902

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop